Taifu Capital

elsewhere's corpus carries no dedicated profile of Taifu Capital (泰福资本) — no founding date, team, or fund size is covered. What it does show is its pattern as an investor: Taifu appears repeatedly as a backer in Qiming Venture Partners–led healthcare rounds, most recently co-participating in Vivatides Therapeutics' oversubscribed $54M Series A in April 2026 , continuing into Minghui Pharmaceutical's $131M pre-IPO round in August 2025 (also noted by 5Y Capital as "existing shareholder Taifu Capital (TF Capital) providing continued support") , and sitting on the shareholder list of Yangli Pharma alongside Hangzhou state capital and Runzhang VC . So the picture that emerges is of a healthcare-focused investor riding alongside Qiming in innovative-drug financings — anything beyond that, elsewhere has not yet covered.